Ipsen Partners with Origami Therapeutics on Protein Degrader Program for Rare Neurodegenerative Diseases
Key Insights
French biopharmaceutical company Ipsen has entered a global collaboration and option agreement with San Diego-based Origami Therapeutics (search) to advance a small-molecule protein degrader program targeting rare, inherited neurodegenerative disorders.
The partnership leverages Origami's proprietary Oricision platform, which designs small-molecule protein degraders (search) capable of engaging the body's natural protein disposal systems to selectively eliminate disease-causing proteins (search) while preserving normal cellular function.
Under the agreement, Ipsen has secured an exclusive option to license the research program worldwide once a drug candidate is nominated, with Origami eligible for upfront payments, milestone-based compensation, and royalties.
French biopharmaceutical company Ipsen has entered a global collaboration and option agreement with San Diego-based biotech Origami Therapeutics (search) to advance a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder. The deal strengthens Ipsen's early-stage neuroscience pipeline while giving Origami a potential path toward global development and commercialization.
Under the agreement, Ipsen has secured an exclusive option to license the research program worldwide once a drug candidate is nominated. If Ipsen activates the option, it will take over responsibility for clinical development and commercialization. Origami will continue leading the research phase and is eligible for upfront payments, milestone-based compensation, and royalties.
Targeting Protein Degradation in Neurodegeneration
The partnership reflects growing interest in protein degradation as a disease-modifying strategy beyond oncology, where the approach first gained traction. In neurodegenerative diseases (search), toxic proteins (search) accumulate over time, damaging neurons and driving irreversible decline. Targeted degradation aims to remove those harmful proteins while preserving normal cellular function.
Origami Therapeutics (search) has built its program on its proprietary Oricision platform, which designs small-molecule protein degraders (search) capable of engaging the body's natural protein disposal systems. Unlike conventional inhibitors, degraders seek to eliminate disease-causing proteins (search) rather than simply blocking their activity. For neurological disorders, small molecules are especially promising because they are more likely to cross the blood–brain barrier, a major challenge in central nervous system drug development.
Small molecule protein-degraders developed using the Oricision technology platform are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins (search) while sparing normal forms of the protein. Origami's technology leveraging small molecules focuses on precision and selectivity, with the goal of limiting off-target effects while addressing the root cause of disease.
Strategic Alignment for Rare Disease Focus
Steve Glyman, senior vice president and head of neuroscience research and development at Ipsen, said the collaboration fits squarely within the company's strategy. "Their approach aligns seamlessly with Ipsen's strong rare neuroscience heritage and expertise in small-molecule innovation, enabling us to advance first- and best-in-class therapies for people living with debilitating conditions where treatment options remain limited," he said.
For Ipsen, the deal adds another preclinical program in rare neurodegenerative diseases (search), an area where few disease-modifying treatments exist. Origami, meanwhile, gains access to a global partner with experience in late-stage development and regulatory pathways.
"Ipsen brings deep expertise in rare neuroscience and global development, making them an ideal partner as we advance this program toward the clinic. Together, we share a commitment to translating cutting-edge biology into meaningful therapies for patients who currently have limited or no treatment options," said Beth Hoffman, Ph.D., Chief Executive Officer and Founder of Origami Therapeutics (search).
Building on Platform Success
Founded to apply protein degradation to disorders of the brain, Origami has advanced multiple discovery programs and positioned its lead candidate in Huntington's disease (search), ORI-113, as a potential proof point for its platform. The collaboration with Ipsen represents a strong validation of Origami's science and of the potential of targeted protein degradation to address the root causes of rare genetic neurodegenerative diseases (search).
The partnership enables both companies to leverage their complementary strengths—Origami's innovative protein degradation technology and Ipsen's global development capabilities—to advance potential first- and best-in-class therapies for patients with debilitating conditions where treatment options remain severely limited.